Navigation Links
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
Date:3/15/2013

SOUTH JORDAN, Utah and PETACH TIKVAH, Israel, March 15, 2013 /PRNewswire/ -- OphthaliX Inc. (OTCBB: OPLI) announced today that it has completed patient enrollment for a Phase 3 clinical study of CF101 for the treatment of Dry Eye Syndrome (DES). The randomized, double-masked study is conducted in the United States, Europe and Israel. The study includes 236 patients with moderate-to-severe DES who are randomized to receive two oral doses of CF101 and a placebo for a period of 24 weeks. The results of this study are expected to be announced in the fourth quarter of 2013.

"We are very pleased to have completed the patient enrollment for our Dry Eye Syndrome study," commented Barak Singer , the CEO of OphthaliX. "Receiving additional clinical data is an important step for OphthaliX as we further develop CF101. We are looking forward to the results of this study which will be released during the fourth quarter this year."  

About OphthaliX Inc.
OphthaliX Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. OphthaliX's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

About CF101
CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug which demonstrated efficacy and an excellent safety profile in Phase 2 clinical studies. CF101 is currently developed for ophthalmic indications, including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).

Contact:
KCSA Strategic Communications
Jeff Corbin / Phil Carlson
jcorbin@kcsa.com / pcarlson@kcsa.com
212-896-1233

This release contains forward-looking statements regarding OphthaliX's future plans and expected performance based on assumptions the Company believes to be reasonable.  A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, the success rate of business development efforts and the timeliness of development activities, and other risk factors described from time to time in the Company's reports filed with the SEC.  In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company's control. OphthaliX undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE OphthaliX Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OphthaliX Reports First Quarter 2012 Financial Results
2. Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
3. ULURU Inc. Announces Closing Of $440,000 Private Placement
4. Cardica Announces Proposed Public Offering of Common Stock
5. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
7. Simbionix Announces License Agreement for Surgical Videos
8. BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
9. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
10. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
11. PDI, Inc. Announces $17 Million Multi-Year Sales Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... MARLTON, N.J. , April 28, 2016   ... solutions, today announced that leading IT market research and ... Player " in the IDC MarketScape: Worldwide Pharmaceutical Track ... March 2016).  The report provides an assessment of the ... pharmaceutical track and trace software market. Logo ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
Breaking Medicine Technology:
(Date:4/30/2016)... MA (PRWEB) , ... April 30, 2016 , ... ... organization, today announced RANKED Health , a program to critically evaluate and ... major goal of the program is to provide independent, unbiased and accurate information ...
(Date:4/30/2016)... , ... April 30, 2016 , ... Orlando-based Maximized Living ... they go for gold in Rio. Under the care of Maximized Living doctors ... , In an unprecedented showing, Maximized Living is sending the largest contingent of elite ...
(Date:4/29/2016)... ... 29, 2016 , ... Memorial Healthcare System Graduate Medical ... (ACGME) that it has received accreditation for its residency program on Physical Medicine ... that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group ... of their physicians has been invited to be a featured speaker at the Texas ... conference on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine ...
Breaking Medicine News(10 mins):